CoPARC: Colorado Pulmonary Alcohol Research Collaborative

项目摘要 拟议的补充将增加一个既定的R24酒精研究资源，称为CoPARC （科罗拉多肺酒精研究协作），这已作为一个人类参与者和病人 支持酒精滥用和肺结核交叉点转化研究的生物储存库 疾病CoPARC以科罗拉多大学为中心，为以下研究项目做出了贡献： 自2011年以来，设立了初级调查员。目前的CoPARC活动涉及收集、处理和 人呼吸道生物标本中的测定。这增加了感染新型严重急性 呼吸道综合征冠状病毒2型（SARS-CoV-2）感染。为了解决这个问题，对CoPARC的修改 现有的基础设施是继续积极合作的必要条件。此外，扩大已批准的研究 研究酒精在冠状病毒病发病机制中的作用的协议 （COVID）-19相关的呼吸衰竭和急性呼吸窘迫综合征（ARDS）计划， CoPARC的合作研究者一致表示支持在这一领域扩大研究。早期 COVID-19相关呼吸衰竭和ARDS患者的报告表明， 免疫反应影响疾病严重程度，导致多器官功能障碍和死亡。重要的是， 有害的酒精使用与肺免疫失调和肺泡毛细血管 这可能解释了其与严重ARDS的一致关联。然而，关系 酒精使用与SARS-CoV-2相关的呼吸道疾病之间的关系仍然未知。该补充将 补充CoPARC的使命，使研究能够描述酒精使用对感染的影响， SARS-CoV-2，包括酒精使用对呼吸衰竭短期和长期结局的作用， ARDS。在CoPARC的主要临床中心，约25%的严重COVID-19患者住院， 科罗拉多大学医院支持定期饮酒，而酒精滥用似乎正在增加 在美国各地流行。因此，饮酒在COVID-19疾病中的作用 发病机制需要进一步研究。这一补充的目的是符合NIAAA的通知， 满足迫切研究需要的特别兴趣是进一步了解酒精相关器官如何 损害可能会使COVID-19的健康结果复杂化，包括：（1）调整现有的CoPARC 基础设施，以安全有效地进行平移肺部检查，以了解 饮酒对SARS-CoV-2感染的影响及其对住院患者短期（即28天）结局的影响 COVID-19相关呼吸衰竭和ARDS住院患者;和（2）在ICU幸存者队列中， 没有COVID-19相关的呼吸衰竭和ARDS，被招募进行CoPARC研究， 出院后进行6个月的纵向随访，包括详细的酒精使用情况 呼吸系统健康的客观评估。

Project Summary The proposed supplement will augment an established R24 Alcohol Research Resource, known as CoPARC (Colorado Pulmonary-Alcohol Research Collaborative), that has served as a human participant and patient biorepository supporting translational investigations at the intersection of alcohol misuse and pulmonary disease. CoPARC is centered at the University of Colorado, and has contributed to the research programs of established and junior investigators since 2011. Current CoPARC activities involve collection, processing, and assays in human respiratory biospecimens. This poses an increased risk for contracting the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To address this issue, modifications to CoPARC's existing infrastructure are necessary to continue active collaborations. Further, extending approved research protocols to conduct investigations delineating alcohol's role in the pathogenesis of Coronavirus Disease (COVID)-19-associated respiratory failure and the acute respiratory distress syndrome (ARDS) are planned, and CoPARC's co-investigators have expressed unanimous support for expanded research in this area. Early reports in patients with COVID-19-associated respiratory failure and ARDS suggest that aberrations in the immune response influence severity of illness, contributing to multi-organ dysfunction and death. Importantly, harmful alcohol use has been associated with dysregulated pulmonary immunity and alveolar-capillary permeability that may explain its consistent association with severe ARDS. Nevertheless, the relationship between alcohol use and SARS-CoV-2-related respiratory illness remains unknown. This supplement will complement CoPARC's mission by enabling studies to delineate the impact of alcohol use on infection due to SARS-CoV-2, including the role of alcohol use on short- and long-term outcomes in respiratory failure and ARDS. Approximately 25% of patients hospitalized with severe COVID-19 at CoPARC's principal clinical site, the University of Colorado Hospital, endorse regular alcohol use, and alcohol misuse appears to be increasing across the US during the pandemic. Therefore, the role of alcohol consumption in COVID-19 disease pathogenesis warrants additional investigation. Aims for this supplement are in line with the NIAAA's notice of special interest to meet urgent research needs to further knowledge regarding how alcohol-associated organ damage may complicate health outcomes in COVID-19, and include: (1) Adapt the existing CoPARC infrastructure to safely and efficiently perform translational pulmonary investigations to understand the role of alcohol use on SARS-CoV-2 infection, and its impact on short-term (i.e. 28 day) outcomes among hospitalized in-patients with COVID-19-related respiratory failure and ARDS; and (2) In a cohort of ICU survivors, with and without COVID-19-associated respiratory failure and ARDS, who are recruited for CoPARC investigations, perform longitudinal follow up for six months following hospital discharge, including detailed alcohol use measures and objective assessments of respiratory health.